Clinical trial Recruiting at 1 site Observational Ages 18 and up

Assessing Lynch Syndrome Frequency in Colorectal Cancer Patients

Official title: Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer

Run by State Scientific Centre of Coloproctology, Russian Federation · NCT05495776 · Data updated 2026-11-12

This study is trying to find out how common Lynch syndrome is in people with colorectal cancer in Russia by looking at their blood and tumor samples over five years.

More Colorectal Cancer trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2500 (estimated)
SponsorState Scientific Centre of Coloproctology, Russian Federation
Government
Drugs / interventionschemotherapy
Locations1 site (Moscow)
StatusRecruiting
StartedAugust 1, 2022
Main results expectedAugust 1, 2025
Study endsDecember 31, 2028
Registry record updatedOctober 25, 2022
Trial IDNCT05495776 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with histologically verified colon adenocarcinoma or synchronous neoplasms who have not received prior treatment for a second tumor.

Probably not a fit

Patients currently undergoing chemotherapy or radiotherapy for colon cancer will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational multicenter registry study aims to evaluate the frequency of Lynch syndrome among patients diagnosed with colorectal cancer in Russia. Blood and tumor samples will be collected from participants, with microsatellite instability assessed through various methods available at the participating centers. The study will follow patients for five years to correlate genetic mutations with clinical data, treatment effectiveness, and familial cancer patterns. The goal is to enhance understanding of Lynch syndrome's impact on treatment strategies in the Russian context.

Why it matters

Potential benefit: If successful, this study could lead to improved identification and management of Lynch syndrome in colorectal cancer patients, potentially enhancing treatment outcomes.

How similar studies have gone: While similar studies have been conducted, this specific multicenter registry approach focusing on Lynch syndrome frequency in colorectal cancer patients is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Provision of written informed consent;
* Patients with histologically verified colon adenocarcinoma or patients with histologically verified synchronous neoplasms who have not previously received treatment for a second tumor;
* Age ≥ 18 years;
* Absence of antitumor treatment for a real tumor (it is allowed to include patients who have a history of antitumor treatment for other malignant tumors, if the period after treatment is more than 12 months).
* The ability of the patient, according to the Researcher, to fulfill the requirements of the Protocol;

Exclusion Criteria:

\- Patients receiving chemotherapy or radiotherapy for colon cancer at the time of screening

Where it's running

  • State Scientific Centre of Coloproctology
    Moscow, Russia
    Recruiting

Study contacts

  • Principal investigator: Alexey Tsukanov, PhD — Head of the Department of Laboratory Genetics
  • Study coordinator: Dmitrii Semenov, PhD
  • Email: dr.semenov@inbox.ru
  • Phone: +7 (985) 2632870

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.